TY - JOUR
T1 - Low-level arsenic causes proteotoxic stress and not oxidative stress
AU - Dodson, Matthew
AU - de la Vega, Montserrat Rojo
AU - Harder, Bryan
AU - Castro-Portuguez, Raul
AU - Rodrigues, Silvia D.
AU - Wong, Pak Kin
AU - Chapman, Eli
AU - Zhang, Donna D.
N1 - Funding Information:
This work was supported by the following grants from the National Institutes of Health : ES023758 (DDZ and EC), ES026845 (DDZ) and DK109555 (DDZ), and ES004940-28 (DDZ).
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/2/15
Y1 - 2018/2/15
N2 - Prolonged exposure to arsenic has been shown to increase the risk of developing a number of diseases, including cancer and type II diabetes. Arsenic is present throughout the environment in its inorganic forms, and the level of exposure varies greatly by geographical location. The current recommended maximum level of arsenic exposure by the EPA is 10 μg/L, but levels > 50–1000 μg/L have been detected in some parts of Asia, the Middle East, and the Southwestern United States. One of the most important steps in developing treatment options for arsenic-linked pathologies is to understand the cellular pathways affected by low levels of arsenic. Here, we show that acute exposure to non-lethal, low-level arsenite, an environmentally relevant arsenical, inhibits the autophagy pathway. Furthermore, arsenite-induced autophagy inhibition initiates a transient, but moderate ER stress response. Significantly, low-level arsenite exposure does not exhibit an increase in oxidative stress. These findings indicate that compromised autophagy, and not enhanced oxidative stress occurs early during arsenite exposure, and that restoring the autophagy pathway and proper proteostasis could be a viable option for treating arsenic-linked diseases. As such, our study challenges the existing paradigm that oxidative stress is the main underlying cause of pathologies associated with environmental arsenic exposure.
AB - Prolonged exposure to arsenic has been shown to increase the risk of developing a number of diseases, including cancer and type II diabetes. Arsenic is present throughout the environment in its inorganic forms, and the level of exposure varies greatly by geographical location. The current recommended maximum level of arsenic exposure by the EPA is 10 μg/L, but levels > 50–1000 μg/L have been detected in some parts of Asia, the Middle East, and the Southwestern United States. One of the most important steps in developing treatment options for arsenic-linked pathologies is to understand the cellular pathways affected by low levels of arsenic. Here, we show that acute exposure to non-lethal, low-level arsenite, an environmentally relevant arsenical, inhibits the autophagy pathway. Furthermore, arsenite-induced autophagy inhibition initiates a transient, but moderate ER stress response. Significantly, low-level arsenite exposure does not exhibit an increase in oxidative stress. These findings indicate that compromised autophagy, and not enhanced oxidative stress occurs early during arsenite exposure, and that restoring the autophagy pathway and proper proteostasis could be a viable option for treating arsenic-linked diseases. As such, our study challenges the existing paradigm that oxidative stress is the main underlying cause of pathologies associated with environmental arsenic exposure.
UR - http://www.scopus.com/inward/record.url?scp=85041399858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041399858&partnerID=8YFLogxK
U2 - 10.1016/j.taap.2018.01.014
DO - 10.1016/j.taap.2018.01.014
M3 - Article
C2 - 29408041
AN - SCOPUS:85041399858
SN - 0041-008X
VL - 341
SP - 106
EP - 113
JO - Toxicology and Applied Pharmacology
JF - Toxicology and Applied Pharmacology
ER -